Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer
Ritu Chaudhary(Moffitt Cancer Center), Christine H. Chung(Moffitt Cancer Center), Gad Getz(Broad Institute), Robbert J.C. Slebos(University of Iowa), Antonio L. Amelio(University of North Carolina at Chapel Hill), José A. Guevara-Patiño(Moffitt Cancer Center), Aik Choon Tan(Colorado School of Public Health), James W. Rocco(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kedar Kirtane(Moffitt Cancer Center), Nabil F. Saba(Emory University), Brian P. Danysh(Broad Institute), Michael J. Schell(University of Bonn), Robin Park(Moffitt Cancer Center), Samuel S. Freeman(Broad Institute), Nicholas J. Haradhvala(Broad Institute), Sowjanya Thatikonda(Johns Hopkins University), Jiannong Li(Moffitt Cancer Center), Yeva Meshkovska(Moffitt Cancer Center), Xiaofei Song(Baylor College of Medicine), Marcelo Bonomi, Graydon Moorhead(Broad Institute), Juan C. Hernandez‐Prera(Moffitt Cancer Center)
Cited by 3
Related Papers
Integrative genomics viewer
|Nature Biotechnology|2011|16.5k
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k